We congratulate our client, Sanofi-Aventis, on the launch of its new prostate cancer treatment, JEVTANA. The FDA approved JEVTANA (cabazitaxel) on June 17, 2010 for use in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with a docetaxel-based treatment regimen. Jevtana is administered intravenously.
Subsequently, Sanofi-Aventis launched JEVTANA in the United States on July 19, 2010. Jevtana in combination with prednisone is the only FDA approved regimen to significantly improve overall survival in patients previously treated with docetaxel-based chemotherapy regimen." Studies have shown that JEVTANA can increase survival by 30%.
We are proud to have played a role in helping Sanofi-Aventis bring this innovative and exciting treatment – and trademark – to market.

Bastille Day
Tuesday, July 13th, 2010À nos clients et collègues français, nous vous souhaitons un joyeux Quatorze Juillet !
Posted in Announcements, Commentary, General | No Comments »